Technical development of a novel vaccine vehicle for cattle pathogens

泰勒锥虫是一种普遍存在于世界各地牛群中的单细胞生物。利用其他锥虫生物的基因表达和蛋白运输的知识，我们成功地开发出泰氏锥虫作为疫苗抗原和治疗药物的递送系统。根据几家动物健康公司的建议，我们现在的目标是开发和展示泰勒氏锥虫作为一种有效和实用的疫苗载体的潜力，为商业化提供一条明确的路线。在两步开发路径中，第一阶段将专注于对疫苗载体在储存和分发期间的可行性进行技术改进和分析。还将建立该系统表达来自一系列病原体的抗原的灵活性。第二阶段将需要确认在第一阶段开发的改进的体内有效性。结合这些实验，将解决这种专利疫苗系统商业开发的关键障碍。

Trypanosoma theileri is a ubiquitous single celled organism present in cattle herds worldwide. Using knowledge of gene expression and protein trafficking in other trypanosomatid organisms, we have successfully developed T. theileri as a delivery system for vaccine antigens and therapeutics. Following recommendations from several Animal Health companies, we now aim to develop and demonstrate the potential of T. theileri as an effective and practical vaccine-vehicle, providing a clear route to commercialisation.In a two-step development path, Phase 1 will focus on technical refinements and analysis of the viability of the vaccine-vehicle during storage and distribution. The flexibility of the system to express antigens from a range of pathogens will also be established. Phase 2 will entail confirmation of the in vivo efficacy of the refinements developed in Phase 1.Combined the experiments will address key hurdles to the commercial development of this patented vaccine system.